[Effects of cilastatin sodium, an inhibitor of dehydropeptidase-I, on human urinary peptide excretion. Patients with renal insufficiency].

Effects of imipenem/cilastatin sodium (IPM/CS), a new parenteral carbapenem combination antibiotic, on the excretion of urinary peptides were investigated by amino acid analysis of these peptides from 12 patients with varying degrees of impairment of renal function, after single or multiple doses (9 doses) of 500 mg/500 mg of the combination drug administered by 30-minute drip infusion. In a single dose study, slight increase in glycine (Gly) were observed in patients with mildly impaired renal function (group I). On the other hand, several amino acids including aspartic acid (Asp), glutamic acid (Glu), Gly and alanine (Ala) were increased in patients with moderately (group II) and severely (group III) impaired renal function.

D-mannose as a preservative of glucose in blood samples.

We evaluated whether any monosaccharides inhibit glycolysis in erythrocytes and discovered that D-mannose does. In the presence of D-mannose, glucose can be accurately measured by either the hexokinase procedure or the glucose oxidase procedure. In comparison studies with other glucose preservatives, we found that after 2 h at room temperature glucose decreased by 21 (SD 13) mg/L in D-mannose-treated blood, 93 (SD 10) mg/L in sodium fluoride-treated blood, 28 (SD 21) mg/L in ice-cooled blood, and 144 (SD 28) mg/L in control blood (no preservative treatment).

[A new anti-cancer agent, bestrabucil (KM 2210): I. Concentration in the serum and tissue in urogenital tumors].

Serum and tissue concentrations of bestrabucil (KM 2210), a combined agent of 17-estradiol and Chlorambucil, were examined in patients with urogenital cancers including those of the kidney, bladder, prostate and testis. We administered orally 100mg (50 mg X 2/day of bestrabucil for 3 days), and determined its plasma levels and metabolites. A maximum drug concentration, i.

Electrical and mechanical interaction between circular and longitudinal muscle layers of the guinea-pig stomach.

The effects of prostaglandin E1 and F2 alpha on the mechanical and electrical responses of circular strips dissected from various parts of the guinea-pig stomach were examined. Prostaglandin E1 induced the tonic contraction without an inhibition of the phasic contraction in lower parts of stomach. The amplitude of tonic contraction decayed along with greater curvature of the stomach, that is, it was largest in pylorus region and smallest in upper corpus.

[Effects of etoposide in testicular tumors].

A clinical study of a new semisynthetic podophyllotoxin etoposide (NK 171) was performed by administering the drug to four patients with testicular tumors. The drug was given intravenously at a dose of 80-120 mg/m2/day for five days or orally at a dose of 200 mg/body/day for five days. Among the four patients, 1 CR, 1 NC and 2 PD were observed.

[Intra-arterial infusion chemotherapy in combination with angiotensin II in advanced bladder cancer].

Intra-arterial infusion chemotherapy in combination with angiotensin II was performed in 5 patients with advanced bladder cancer (all T3M0). The infusion catheter was inserted from a femoral artery into the internal iliac artery. The basic dosage was 70 mg/m2 of Cis-diammine-dichloroplatinum (CDDP) and 40 mg/m2 of Adriamycin (ADM) or 4'-0-tetrahydropyranyl-ADM (THP) in combination with 20-40 micrograms angiotensin II over a total duration of 20 minutes for both sides.

Follow-up study of patients with vibration syndrome in Japan.

This study was performed on 187 patients with vibration syndrome treated and followed for more than five years in 10 hospitals in Japan. The subjects had disturbances of circulation and sensation in their fingers and of joint movements in their upper extremities. Most of the patients received treatment combining physical and drug therapy.

Defibrinogating therapy for peripheral circulatory disturbance in patients with vibration syndrome.

This study examines the effects of batroxobin (a defibrinogating drug) on the peripheral circulatory disturbance of 118 patients with vibration syndrome. In 53 cases, batroxobin was intravenously administered once a day for three successive days in the order of 20, 10, and 5 batroxobin units (BU), and 5 or 10 BU were supplemented every day or every second day, respectively, for four weeks. In these cases, the blood fibrinogen and viscosity decreased.

Intravesical chemotherapy with 4'-epi-Adriamycin in patients with superficial bladder tumors.

We evaluated the effects of 4'-epi-Adriamycin (EPI), a derivative of Adriamycin (ADR), in intravesical instillation chemotherapy. The patients received two courses of three daily instillations of 50-80 mg EPI dissolved in 30 ml physiological saline on 3 consecutive days, with an interval of 4 days between courses. Full evaluation was possible in 33 of 35 patients with superficial bladder tumors treated with EPI.

[Intravesical chemotherapy with 4'-EPI-adriamycin in patients with superficial bladder tumors (randomized study)].

Thirty-seven cases of superficial bladder cancer were treated with 4'-epi-adriamycin (EPI) by intravesical instillation to investigate the optimal dosage and treatment schedule. Patients were randomized into either group A: 50 mg/day for 6 days (regimen A) or group B: 60 mg/day for 3 days X 2 courses with 4 days interval (regimen B). Seventeen cases were evaluated in both groups, three cases were ineligible in group B.

[Combination chemotherapy with cisplatin, ifosfamide and adriamycin in patients with advanced transitional cell carcinoma of the urinary tract].

A combined chemotherapy with cisplatin, ifosfamide and adriamycin (CIA therapy) was performed in 20 patients with advanced transitional cell carcinoma of the urinary tract. Adriamycin 30mg/m2 and ifosfamide 1.5g/m2 were administered on day 1 and cisplatin 50 mg/m2 on day 2, which was repeated at intervals of 3 weeks, in principle.

[Intravesical chemotherapy with 4'-Epi-Adriamycin in patients with superficial bladder tumors].

Intravesical instillation of anticancer agents is one of the most effective methods for treating superficial bladder cancer. We evaluated the effects of including 4'-Epi-Adriamycin, a derivative of Adriamycin, in intravesical instillation chemotherapy. Thirty-five patients with superficial bladder tumors were treated with 4'-Epi-Adriamycin.